Published in Medical Letter on the CDC and FDA, January 2nd, 2005
The company reaffirmed its 2004 guidance of $23 to $24 million in total revenue including $10.5 to $11.0 million in revenue from Xyrem, the first and only approved treatment for cataplexy associated with narcolepsy.
The company also announced that its supplemental New Drug Application (sNDA) filing to expand the Xyrem label to encompass improvement in the other primary symptoms of narcolepsy is expected to be submitted to the U.S. Food and Drug Administration in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA